“童颜针”又有新玩家！心血管器械龙头正式入局

Group 1 - The core point of the article is that Lepu Medical has received approval for its self-developed polylactic acid facial filler, marking a significant milestone in the company's entry into the dermatology field and consumer healthcare sector [1] - The polylactic acid facial filler, known as "童颜针" (youthful needle), is designed to correct facial contours and fill in wrinkles by injecting polylactic acid (PLLA) into the deep dermis [1] - The main component, PLLA, is a microparticle injectable powder that is biocompatible, biodegradable, and safe, breaking down into carbon dioxide and water without long-term effects on the body [1] Group 2 - The approval of the product is expected to positively impact the company's business development and signifies its commitment to the dermatology market [1] - Other companies involved in similar products include Aimeike, Jiangsu Wuzhong, and Huadong Medicine, each with their own polylactic acid-based fillers that have received regulatory approval [4] - The market for injectable regenerative materials in China is estimated to be around 3 billion yuan, with polylactic acid products having the most approvals among the 11 products from 9 companies [5]